DNA-methylation analysis identifies the E-cadherin gene as a potential marker of disease progression in patients with monoclonal gammopathies

Cancer

Volumn 100, Issue 12, 2004, Pages 2598-2606

  Seidl, Sonja ^a   Ackermann, Jutta ^a   Kaufmann, Hannes ^a   Keck, Andrea ^b   Nösslinger, Thomas ^c   Zielinski, Christoph C ^a   Drach, Johannes ^a   Zöchbauer Müller, Sabine ^a,d  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b Wilhelminenspital ^*  (Austria)

^c V Department of Internal Medicine   (Austria)

^d UNIVERSITY OF VIENNA   (Austria)

Author keywords

E cadherin; Methylation; Monoclonal gammopathy of undetermined significance; Myeloma; Tumor suppressor genes

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2B; DEATH ASSOCIATED PROTEIN KINASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN P15; PROTEIN P16INK4A; PROTEIN P73; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOIC ACID RECEPTOR; TISSUE INHIBITOR OF METALLOPROTEINASE; UNCLASSIFIED DRUG; UVOMORULIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DNA METHYLATION; FEMALE; GENE FREQUENCY; GENE IDENTIFICATION; GENE SILENCING; GENETIC ANALYSIS; GENETIC MARKER; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; MYELOMA; PATHOGENESIS; PLASMA CELL LEUKEMIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

AGED; CADHERINS; DISEASE PROGRESSION; DNA METHYLATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PARAPROTEINEMIAS; POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 2642532716     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20295     Document Type: Article

References (55)

1. Kyle RA. Plasma cell proliferative disorders. In: Hoffman R, editor. Hematology: basic principles and practice (3rd edition). New York: Churchill Livingstone, 1999:1021-1038.
2. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564-569.
3. Drach J, Kaufmann H, Urbauer E, Schreiber S, Ackermann J, Huber H. The biology of multiple myeloma. J Cancer Res Clin Oncol. 2000;126:441-447.
4. Zandecki M, Lai JL, Facon T. Multiple myeloma: almost all patients are cytogenetically abnormal. Br J Haematol. 1996; 94:217-227.
5. Seidl S, Kaufmann H, Drach J. New insights into the pathophysiology of multiple myeloma. Lancet Oncol. 2003;4:557-564.
6. Kyle RA. Prognostic factors in multiple myeloma. Stem Cells. 1995;2:56-63.
7. Zojer N, Königsberg R, Ackermann J, et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood. 2000;95: 1925-1930.
8. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3:415-428.
9. Zöchbauer-Müller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res. 2001; 61:249-255.
10. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res. 2001;61: 3225-3229.
11. Ueki T, Toyota M, Sohn T, et al. Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res. 2000; 60:1835-1839.
12. Toyota M, Kopecky KJ, Toyota MO, Jair KW, Willman CL, Issa JP. Methylation profiling in acute myeloid leukemia. Blood. 2001;97:2823-2829.
13. Gonzalez M, Mateos MV, Garcia-Sanz R, et al. Dae novo methylation of tumor suppressor gene p16/INK4a is a frequent finding in multiple myeloma patients at diagnosis. Leukemia. 2000;14:183-187.
14. INK4b gene methylations in plasma cells from monoclonal gammopathy of undetermined significance. Blood. 2001; 98:244-246.
15. Ng MH, To KW, Lo KW, et al. Frequent death-associated protein kinase promoter hypermethylation in multiple myeloma. Clin Cancer Res. 2001;7:1724-1729.
16. Galm O, Yoshikawa H, Esteller M, Osieka R, Herman JG. SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood. 2002;27:2784-2788.
17. Galm O, Jost E, Fabry U, Gehbauer G, Herman JG, Osieka R. Aberrant methylation of the E-cadherin 5′ CpG island occurs with disease progression in multiple myeloma. Presented at the Seventh Annual Meeting of the European Hematology Association, Florence, Italy, June 6-9, 2002.
18. Burbee DG, Forgacs E, Zöchbauer-Müller S, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst. 2001; 93:691-699.
19. Virmani AK, Rathi A, Zöchbauer-Müller S, et al. Promoter methylation and silencing of the retinoic acid receptor-β gene in lung carcinomas. J Natl Cancer Inst. 2000;92:1303-1307.
20. Bachman KE, Herman JG, Corn PG, et al. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res. 1999;59:798-802.
21. Katzenellenbogen RA, Baylin SB, Herman JG. Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood. 1999;93:4347-4353.
22. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999;59:793-797.
23. Merlo A, Herman JG, Mao L, et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med. 1995;1:686-692.
24. Herman JG, Jen J, Merlo A, Baylin SB. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res. 1996;56:722-727.
25. ARF locus with reduced mRNA expression in colorectal cancer cell lines and clinicopathological features in primary tumors. Carcinogenesis. 2000;21:2057-2064.
26. Corn PG, Kuerbitz SJ, van Noesel MM, et al. Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5′ CpG island methylation. Cancer Res. 1999;59:3352-3356.
27. Graff JR, Gabrielson E, Fujii H, Baylin SB, Herman JG. Methylation patterns of the E-cadherin 5′ CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J Biol Chem. 2000;275:2727-2732.
28. Liu M, Taketani T, Li R, et al. Loss of p73 gene expression in lymphoid leukemia cell lines is associated with hypermethylation. Leuk Res. 2001;25:441-447.
29. 6-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Natl Cancer Inst. 2002;94:26-32.
30. Maruyama R, Toyooka S, Toyooka KO, et al. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res. 2001;61: 8659-8663.
31. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual (2nd edition). Cold Spring Harbor: Cold Spring Harbor Laboratory Press, 1989.
32. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996;93:9821-9826.
33. Maruyama R, Toyooka S, Toyooka KO, et al. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res. 2002;8:514-519.
34. Virmani AK, Muller C, Rathi A, Zöchbauer-Müller S, Mathis M, Gazdar AF. Aberrant methylation during cervical carcinogenesis. Clin Cancer Res. 2001;7:584-589.
35. KIP2 gene in the promoter region in lymphoid malignancies of B-cell phenotype. Blood. 2002;100:2572-2577.
36. Mateos MV, Gonzalez M, Balanzategui A, et al. Status of methylation of p16 gene in multiple myeloma: a comparative study of three methods for its detection. Clin Biochem. 2000;33:415-418.
37. INK4A gene in multiple myeloma. Br J Haematol. 1998; 101:558-564.
38. Chen CY, Tsay W, Tang JL, et al. SOCS1 methylation in patients with newly diagnosed acute myeloid leukemia. Genes Chromosomes Cancer. 2003;37:300-305.
39. Voso MT, Scardocci A, Guidi F, et al. Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes. Blood. 2004;103:698-700.
40. Mateos MV, Garcia-Sanz R, Lopez-Perez R, et al. p16/INK4a gene inactivation by hypermethylation is associated with aggressive variants of monoclonal gammopathies. Hematol J. 2001;2:146-149.
41. Mateos MV, Garcia-Sanz R, Lopez-Perez R, et al. Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival. Br J Haematol. 2002;118:1034-1040.
42. Fonseca R, Bailey RJ, Ahmann GJ, et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood. 2002;100:1417-1424.
43. Zhan F, Hardin J, Kordsmeier B, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood. 2002;99:1745-1757.
44. Bremnes RM, Veve R, Hirsch FR, Franklin WA. The E-cadherin cell-cell adhesion complex and lung cancer invasion, metastasis, and prognosis. Lung Cancer. 2002;36:115-124.
45. Cavallaro U, Schaffhauser B, Christofori G. Cadherins and the tumour progression: is it all in a switch? Cancer Lett. 2002;176:123-128.
46. Melki JR, Vincent PC, Brown RD, Clark SJ. Hypermethylation of E-cadherin in leukemia. Blood. 2000;95:3208-3213.
47. Corn PG, Smith BD, Ruckdeschel ES, Douglas D, Baylin SB, Herman JG. E-cadherin expression is silenced by 5′ CpG island methylation in acute leukemia. Clin Cancer Res. 2000; 6:4243-4248.
48. Wijermans P, Lubbert M, Verhoef G, et al. Low-dose 5-aza-2′ -deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter Phase II study in elderly patients. J Clin Oncol. 2000; 18:956-962.
49. Kantarjian HM, O'Brien SM, Estey E, et al. Decitabine studies in chronic and acute myelogenous leukemia. Leukemia. 1997;11:S35-S36.
50. De Lima M, Ravandi F, Shahjahan M, et al. Long-term follow-up of a Phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. Cancer. 2003;97: 1242-1247.
51. Shaker S, Bernstein M, Momparler LF, Momparler RL. Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2′-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells. Leuk Res. 2003;27:437-444.
52. Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, Herman JG. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet. 2001;10:687-692.
53. Wong IH, Ng MH, Lee JC, Lo KW, Chung YF, Huang DP. Transcriptional silencing of the p16 gene in human myeloma-derived cell lines by hypermethylation. Br J Haematol. 1998;103:168-175.
54. Lo YM, Wong IH, Zhang J, Tein MS, Ng MH, Hjelm NM. Quantitative analysis of aberrant p16 methylation using real-time quantitative methylation-specific polymerase chain reaction. Cancer Res. 1999;59:3899-3903.
55. Danbara M, Kameyama K, Higashihara M, Takagaki Y. DNA methylation dominates transcriptional silencing of Pax5 in terminally differentiated B cell lines. Mol Immunol. 2002;38: 1161-1166.